Trump says Exxon and Chevron made ‘too much money’ during Iran conflict
President Donald Trump said Monday that ExxonMobil and Chevron made “too much money” on rising…
Trump says Exxon and Chevron made ‘too much money’ during Iran conflict
President Donald Trump said Monday that ExxonMobil and Chevron made “too much money” on rising crude oil prices due to the Iran war. “They’re making too much money based on a shortage,” Trump told reporters at the White House. “I don’t like it.” Exxon and Chevron on Friday reported windfall profits for the second quarter….
‘The Odyssey’ fuels all-time high
Imax is on a winning streak, and it has Christopher Nolan to thank. Shares of the entertainment technology company hit an all-time high Monday as it continues to haul in box office receipts from Nolan’s “The Odyssey.” Imax CEO Rich Gelfond said Monday the film is tracking almost double what Nolan’s “Oppenheimer” raked in in 2023….
FAA clears smallest Boeing 737 Max to fly after years of delays
The Federal Aviation Administration has certified the Boeing 737 Max 7, the smallest model in the best-selling family of aircraft, after nearly a decade of delays. The agency on Monday said the approval “reflects years of sustained work to resolve complex technical issues and complete a thorough review of the airplane’s design and supporting safety…
White House to host AI companies to review new model-testing framework
US President Donald Trump (R) and Open AI CEO Sam Altman (L) react during a working lunch meeting of G7 members, partner countries, and artificial intelligence business leaders as part of the G7 summit, in Evian, eastern France, on June 17, 2026. Julia Demaree Nikhinson | Afp | Getty Images The White House will host…
Amazon tops $3 trillion market cap as stock continues to surge
Shares of Amazon hit a new all-time high on Monday, putting its market cap over the $3 trillion threshold following a better-than-expected earnings report last week. Monday’s new record is the best day for Amazon since May 5. Shares are up roughly 4%. The jump comes after the company reported a surge in cloud growth…
Visa to buy fraud-detection firm BioCatch for $2.4 billion
Nikolas Kokovlis | Nurphoto | Getty Images Visa on Monday said it is acquiring fraud detection startup BioCatch for $2.4 billion in cash, expanding the payment giant’s push into cybersecurity as banks confront a surge in artificial intelligence-powered scams and account takeovers. Under the deal, Visa will get BioCatch’s behavioral biometrics platform, which analyzes data…
Jim Cramer’s top 10 things to watch in the stock market Monday
My top 10 things to watch Monday, Aug. 3 1. Peace talks between the U.S. and Iran are back on the menu, so oil prices are falling. WTI crude is off more than 5%, trading below $80 a barrel this morning. Stock futures are higher across the board, led by the Dow . Within our…
Pictures show firefighters battling raging wildfires in Greece
Firefighters and Hellenic Civil Protection personnel battle advancing flames during a wildfire near Agios Nektarios in Western Attica, Greece, as firefighting operations continue under difficult conditions. Nick Paleologos | Afp | Getty Images Greece is entering its second week of wildfires spread by extreme winds as more countries in Southern Europe battle with heatwaves. The…
ChatGPT accounts for 80% of identifiable House AI spending
OpenAI CEO Sam Altman speaks with reporters following meetings on Capitol Hill, in Washington, June 3, 2026. Evelyn Hockstein | Reuters OpenAI is dominating the first visible wave of artificial intelligence spending inside Congress. The maker of ChatGPT accounted for roughly $9 out of every $10 spent on identifiable AI tools by House offices, committees…
AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
AstraZeneca shares dropped as much as 7% after a report that the U.K.’s largest drugmaker was in talks with U.S. peer Bristol Myers Squibb over a megadeal that, if completed, could value the companies at roughly $400 billion. AstraZeneca declined to comment. Bristol Myers Squibb didn’t immediately respond to a request to comment outside of…
